24 results on '"Arhin, Francis"'
Search Results
2. Critical Factors of Digital Supply Chains for Organizational Performance Improvement
3. Ceftazidime-avibactam activity against Gram-negative respiratory isolates collected between 2018 and 2019
4. In vitro activity of aztreonam/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019
5. Molecular characterization of clinical isolates of Enterobacterales with elevated MIC values for aztreonam-avibactam from the INFORM global surveillance study, 2012–2017
6. 13: IN VITRO ACTIVITY OF CEFTAZIDIME-AVIBACTAM AND AZTREONAM-AVIBACTAM AGAINST CARBAPENEM-NONSUSCEPTIBLE ENTEROBACTERALES ISOLATES COLLECTED IN ASIA/PACIFIC FROM 2017–2020 AS PART OF THE ATLAS GLOBAL SURVEILLANCE PROGRAm
7. 11: IN VITRO ACTIVITY OF AZTREONAM-AVIBACTAM AGAINST ENTEROBACTERALES ISOLATES THAT CARRY METALLO-β-LACTAMASES COLLECTED IN THE ASIA/PACIFIC REGIONAS A PART OF THE ATLAS GLOBAL SURVEILLANCE PROGRAM FROM 2015–2020
8. Comparative In VitroActivities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureusIsolates in a Nondividing State
9. Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility
10. Use of In VitroVancomycin Testing Results To Predict Susceptibility to Oritavancin, a New Long-Acting Lipoglycopeptide
11. Pharmacodynamics of a Simulated Single 1,200-Milligram Dose of Oritavancin in an In VitroPharmacokinetic/Pharmacodynamic Model of Methicillin-Resistant Staphylococcus aureusInfection
12. Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates
13. Oritavancin Kills Stationary-Phase and Biofilm Staphylococcus aureusCells In Vitro
14. Effect of Polysorbate 80 on Oritavancin Binding to Plastic Surfaces: Implications for Susceptibility Testing
15. Outer Membrane Proteins and Serosubtyping with Outer Membrane Vesicles from Clinical Isolates of Neisseria meningitidis
16. Oritavancin Disrupts Membrane Integrity of Staphylococcus aureusand Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing
17. Assessment of Oritavancin Serum Protein Binding across Species
18. Impact of Human Serum Albumin on Oritavancin In Vitro Activity against Enterococci
19. Assessment by Time-Kill Methodology of the Synergistic Effects of Oritavancin in Combination with Other Antimicrobial Agents against Staphylococcus aureus
20. Assessment of the potential for oritavancin MIC changes among Staphylococcus aureusnasal carriage isolates following systemic oritavancin treatment in a phase 2 study in patients with acute bacterial skin and skin-structure infections
21. Agar dilution minimum inhibitory concentrations under-represent oritavancin in vitro activity against staphylococci and enterococci
22. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faeciumIsolates with or without Reduced Susceptibility to Daptomycin in an In VitroPharmacokinetic/Pharmacodynamic Model
23. Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faeciumIsolates in an In VitroPharmacokinetic/Pharmacodynamic Model of Infection
24. Characterization of the In Vitro Activity of Novel Lipoglycopeptide Antibiotics
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.